Table 3.

Correlation of SMAD gene expression level with overall survival (OS) of gastric cancer patients of different genders

SMADs	Gender	Cases	HR (95% CI)	P-value
SMAD1	Female	187	0.39 (0.21 − 0.7)	0.0011*
	Male	349	0.65 (0.48 − 0.87)	0.0038*
SMAD2	Female	236	0.53 (0.36 − 0.8)	0.0021*
	Male	545	0.48 (0.36 − 0.62)	3.9e−08*
SMAD3	Female	236	2.26 (1.57 − 3.25)	6.2e−06*
	Male	545	1.83 (1.47 − 2.27)	3.3e−08*
SMAD4	Female	236	0.62(0.44–0.88)	0.0075*
	Male	545	0.55 (0.43 − 0.71)	1.4e−06*
SMAD5	Female	236	1.27 (0.9 − 1.81)	0.17
	Male	415	1.41 (1.14 − 1.75)	0.0015*
SMAD6	Female	236	1.73 (1.21 − 2.48)	0.0023*
	Male	545	1.38 (1.1 − 1.73)	0.0053*
SMAD7	Female	236	1.64 (1.15 − 2.35)	0.0059*
	Male	495	1.17 (0.93 − 1.48)	0.17
SMAD9	Female	187	2.54 (1.38 − 4.67)	0.002*
	Male	349	1.66 (1.23 − 2.22)	0.00068*

*P < 0.05

Abbreviations: CI, confidence interval; HR, hazard ratio.